Lipocine Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lipocine Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.98M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $11.20M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($2.85M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $500.0K | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $16.14M | Mar 10, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $165.0K | Mar 11, 2021 |
| FY2018 | Dec 31, 2018 | $0 | Mar 6, 2019 |
| FY2018 | Sep 30, 2018 | $0 | Mar 6, 2019 |
| FY2018 | Jun 30, 2018 | $0 | Mar 6, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $500.0K | Mar 10, 2023 |
| FY2022 | Dec 31, 2021 | $16.14M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 9, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.63M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $8.4K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($16.35M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($10.76M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($634.4K) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($20.96M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($13.01M) | Mar 11, 2021 |
| FY2018 | Dec 31, 2018 | ($3.23M) | Mar 6, 2019 |
| FY2018 | Sep 30, 2018 | ($2.46M) | Mar 6, 2019 |
| FY2018 | Jun 30, 2018 | ($3.26M) | Mar 6, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.37M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($1.16M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($17.93M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($12.12M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $3.15M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($18.00M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($12.90M) | Mar 11, 2021 |
| FY2018 | Dec 31, 2018 | ($3.17M) | Mar 6, 2019 |
| FY2018 | Sep 30, 2018 | ($2.35M) | Mar 6, 2019 |
| FY2018 | Jun 30, 2018 | ($3.16M) | Mar 6, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.01M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $22.51M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $23.00M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $37.54M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $52.48M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $25.35M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $19.66M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $20.85M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $25.33M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $27.34M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.53M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.51M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $2.63M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.91M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $6.91M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $10.01M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $13.37M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $11.42M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $6.35M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $1.33M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.48M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $21.00M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $20.37M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $35.63M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $45.57M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $15.34M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $6.29M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $9.43M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $18.98M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $26.02M | Mar 6, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 11, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Mar 6, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Mar 6, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Mar 6, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Mar 6, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 11, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Mar 6, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Mar 6, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Mar 6, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Mar 6, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.21M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $6.21M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $4.77M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.15M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $2.95M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $19.22M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $9.73M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $8.08M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.21M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $5.56M | Mar 12, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.67M | Mar 9, 2022 |
| FY2020 | Dec 31, 2020 | $5.00M | Mar 11, 2021 |
| FY2019 | Dec 31, 2019 | $6.67M | Mar 13, 2020 |
| FY2018 | Dec 31, 2018 | $10.00M | Mar 6, 2019 |